OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugates (tADC)-Based Therapeutic Candidates

OS Therapies (NYSE American: OSTX) (“OS Therapies” or the “Company”), a clinical-stage immunotherapy and antibody drug conjugate (ADC) biopharmaceutical company, today announced development and in vitro concept data for two novel ADC therapeutic candidates utilizing the Company’s proprietary SiLinker technology. The Company has completed target engagement testing for both therapeutic candidates and confirmed their therapeutic potential. These novel constructs target breast, lung and gastric cancers; and ovarian, fallopian tube and primary peritoneal cancers, respectively.

The Company is advancing its tADC platform through successive de-risking milestones in product development and plans to out-license certain therapeutic candidates and compounds that are strategic to potential partners’ pipelines – most notably the pH-sensitive SiLinker. The Company’s first tADC asset, OST-tADC-FRα-H, has achieved proof of concept in animal models of ovarian cancer. With the two additional constructs now added to the pipeline, the Company is positioning itself to become a key supplier of intellectual property for the development of novel therapeutic products to partners, all while continuing to focus its internal resources on commercializing its OST-HER2 immunotherapy cancer vaccine platform for dogs with osteosarcoma and for humans with osteosarcoma and other HER2-positive cancers such as breast and colorectal cancer.